Literature DB >> 15217829

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis.

Steven Le Gouill1, Klaus Podar, Martine Amiot, Teru Hideshima, Dharminder Chauhan, Kenji Ishitsuka, Shaji Kumar, Noopur Raje, Paul G Richardson, Jean-Luc Harousseau, Kenneth C Anderson.   

Abstract

Interleukin-6 (IL-6) triggers multiple myeloma (MM) cell proliferation and protects against apoptosis by up-regulating myeloid cell leukemia 1 (Mcl-1). Vascular endothelial growth factor (VEGF) induces modest proliferation of MM cells and induces IL-6 secretion in a paracrine loop involving MM cells and bone marrow stromal cells. Using murine embryonic fibroblast cell lines as a model (Mcl-1(wt/wt) and Mcl-1(Delta/null) MEFs), we here demonstrate that deletion of Mcl-1 reduces fetal bovine serum (FBS)-, VEGF-, and IL-6-induced proliferation. We also show that VEGF up-regulates Mcl-1 expression in a time- and dose-dependent manner in 3 human MM cell lines and MM patient cells. Importantly, we demonstrate that the pan-VEGF inhibitor, GW654652, inhibits VEGF-induced up-regulation of Mcl-1 and, as with Mcl-1 siRNA, is associated with decreased proliferation and induction of apoptosis. Finally, we show that VEGF protects MM patient cells against FBS starvation-induced apoptosis. Our studies therefore demonstrate that VEGF-induced MM cell proliferation and survival are mediated via Mcl-1, providing the preclinical framework for novel therapeutics targeting Mcl-1 and/or VEGF to improve patient outcome in MM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15217829     DOI: 10.1182/blood-2004-05-1760

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

Authors:  Mark F van Delft; Andrew H Wei; Kylie D Mason; Cassandra J Vandenberg; Lin Chen; Peter E Czabotar; Simon N Willis; Clare L Scott; Catherine L Day; Suzanne Cory; Jerry M Adams; Andrew W Roberts; David C S Huang
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

Review 2.  Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Authors:  Tariq I Mughal; Saulius Girnius; Steven T Rosen; Shaji Kumar; Adrian Wiestner; Omar Abdel-Wahab; Jean-Jacques Kiladjian; Wyndham H Wilson; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-02-17

3.  Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma.

Authors:  Yun Xiang; Elizabeth R Remily-Wood; Vasco Oliveira; Danielle Yarde; Lili He; Jin Q Cheng; Linda Mathews; Kelly Boucher; Christopher Cubitt; Lia Perez; Ted J Gauthier; Steven A Eschrich; Kenneth H Shain; William S Dalton; Lori Hazlehurst; John M Koomen
Journal:  Mol Cell Proteomics       Date:  2011-08-16       Impact factor: 5.911

Review 4.  The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy.

Authors:  P N Kelly; A Strasser
Journal:  Cell Death Differ       Date:  2011-03-18       Impact factor: 15.828

5.  Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo.

Authors:  Emma M Carrington; Yifan Zhan; Jamie L Brady; Jian-Guo Zhang; Robyn M Sutherland; Natasha S Anstee; Robyn L Schenk; Ingela B Vikstrom; Rebecca B Delconte; David Segal; Nicholas D Huntington; Philippe Bouillet; David M Tarlinton; David Cs Huang; Andreas Strasser; Suzanne Cory; Marco J Herold; Andrew M Lew
Journal:  Cell Death Differ       Date:  2017-03-31       Impact factor: 15.828

Review 6.  Preclinical studies of novel targeted therapies.

Authors:  Teru Hideshima; Kenneth C Anderson
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

7.  Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.

Authors:  Karène Mahtouk; Jérôme Moreaux; Dirk Hose; Thierry Rème; Tobias Meissner; Michel Jourdan; Jean François Rossi; Steven T Pals; Hartmut Goldschmidt; Bernard Klein
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

Review 8.  Recent advances in antimultiple myeloma drug development.

Authors:  Nuozhou Wang; Patrick Bartlow; Qin Ouyang; Xiang-Qun Xie
Journal:  Pharm Pat Anal       Date:  2014-05

9.  Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.

Authors:  V Ramakrishnan; M Timm; J L Haug; T K Kimlinger; L E Wellik; T E Witzig; S V Rajkumar; A A Adjei; S Kumar
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

10.  Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells.

Authors:  Shumin Zhang; Haiyen E Zhau; Adeboye O Osunkoya; Shareen Iqbal; Xiaojian Yang; Songqing Fan; Zhengjia Chen; Ruoxiang Wang; Fray F Marshall; Leland W K Chung; Daqing Wu
Journal:  Mol Cancer       Date:  2010-01-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.